EHA2024レポート① Late-breaking Session

再発・難治性DLBCLに対するglofitamab＋GemOxは
リツキシマブ＋GemOxに比し有意にOSを延長 Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) for Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Results of a Global Randomized Phase III Trial (STARGLO) (#LB3438)

Jeremy Abramson（Massachusetts General Hospital Cancer Center, Boston, MA, USA）